DN 1924

Drug Profile

DN 1924

Alternative Names: Dantôn; DN-1924

Latest Information Update: 31 Mar 2008

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hodgkin's disease; Leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Apr 2006 This compound is still in active development
  • 25 Oct 2000 Preclinical development for Hodgkin's disease in USA (Parenteral)
  • 25 Oct 2000 Preclinical development for Leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top